Karin Jooss
Directeur Technique/Scientifique/R&D chez GRITSTONE BIO, INC.
Fortune : 340 443 $ au 30/04/2024
Postes actifs de Karin Jooss
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GRITSTONE BIO, INC. | Directeur Technique/Scientifique/R&D | 13/04/2016 | - |
| FATE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 14/03/2019 | - |
| Independent Dir/Board Member | 14/03/2019 | - |
Historique de carrière de Karin Jooss
Anciens postes connus de Karin Jooss
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/05/2009 | 01/04/2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Directeur Technique/Scientifique/R&D | 01/07/2001 | 01/04/2009 |
Formation de Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Allemagne | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GRITSTONE BIO, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Bourse
- Insiders
- Karin Jooss
- Expérience
